Zimmer Biomet Holdings (ZBH) has drawn fresh attention after a recent share move, with the price closing at US$91.57. Investors are weighing that level against the firm’s broader return record.
The latest 3.72% one day share price return for Zimmer Biomet Holdings comes after a period where the 30 day share price return declined 6.63%. The year to date share price return is up 1.72%, while the 1 year total shareholder return is down 6.35% and the 5 year total shareholder return has declined 31.38%, which points to short term momentum picking up against a weaker long term record.
Scan how Zimmer Biomet Holdings compares with other medical and healthcare names that analysts have filtered for resilient fundamentals using the list of solid balance sheet and fundamentals (25 results).
Zimmer Biomet Holdings trades at a steep implied discount to one valuation estimate and sits below analyst targets after this latest bounce. Is that a mispricing, or is the market simply bracing for more modest return potential?
Most Popular Narrative: 15% Undervalued
Zimmer Biomet Holdings is priced at $91.57 against a widely followed fair value estimate of $107.57, so the current debate centers on whether execution and margins eventually close that gap.
The main factor that has to go right is successful execution of the commercial and cost-efficiency programs, including Project Optima, the global capability center in India, the Costa Rica plant, and integration of acquisitions such as Paragon 28 and iovera, while managing pressure on gross and operating margins.
The shift of R&D activities to a global capability center in India together with the build out of a manufacturing plant in Costa Rica signals a multi year cost structure reset that could ease manufacturing and engineering expenses, which would be supportive of gross margin and operating margin once initial investments and restructuring charges pass.
See why 36 investors see Zimmer Biomet Holdings as 15% undervalued.
Result: Fair Value of $107.57 (UNDERVALUED)
Still, the thesis can be shaken if pricing pressure continues to weigh on margins and if the manufacturing overhaul in Switzerland and Costa Rica disrupts operations.
Find out about the key risks to this Zimmer Biomet Holdings narrative.
Next Steps
Mixed messages about Zimmer Biomet Holdings can be useful if you treat them as prompts rather than answers. Act while the numbers are fresh and weigh both sides for yourself with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Zimmer Biomet Holdings?
Do not stop with Zimmer Biomet Holdings when there are other opportunities worth your attention. Broaden your watchlist and let data driven filters surface fresh ideas built around different risk and income profiles.
- Target dependable cash generators by scanning companies with resilient financial footing using the list of solid balance sheet and fundamentals (25 results).
- Pursue value focused opportunities by reviewing the 27 high quality undervalued stocks that currently combine quality fundamentals with lower implied expectations.
- Strengthen your income stream by searching for reliable payers through the 7 dividend fortresses that emphasize higher yields backed by fundamental checks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com